Growth arrest-specific gene (Gas) 6 is a Gla domain-containing protein which shares 43% amino acid identity with protein S. Gas6 has been shown to enhance cancer cell proliferation in vitro. On the other hand, recent studies have demonstrated that Gas6
Introduction
Colorectal cancer is one of the most common cancers in the world. To discover novel therapeutic strategies, the mechanisms of colorectal cancer development should be understood. In contrast to other cancers, colorectal cancer develops in a unique organ that harbors a vast population of microbes [1] . Accumulating evidence has indicated a crucial role of Toll-like receptor (TLR) signaling in the interaction between luminal microbes and intestinal tumorigenesis [2] [3] [4] .
TAM tyrosine kinase receptors (Tyro3, Axl, and Mer) exert pleiotropic effects [5] .
Recent studies have shown that TAM receptors inhibit TLR-mediated inflammatory responses in dendritic cells and macrophages [5, 6] . Tyro3 -/-Axl -/-Mer -/-triple knockout mice exhibit a broad spectrum of autoimmune diseases [7] . TAM receptors share two humoral ligands: protein S and growth arrest-specific gene 6 (Gas6) [8, 9] . Protein S is a well-defined vitamin-K-dependent plasma glycoprotein that serves as a cofactor of protein C in the inactivation of Factor Va and VIIIa in the anti-coagulation pathway.
Gas6 is a -carboxyglutamic acid (Gla) domain-containing protein that was originally described in growth-arrested fibroblasts [10, 11] . Gas6 has the same domain organization as, and 43% amino acid identity with, protein S, and has the potential to induce platelet-mediated thrombosis. Both protein S and Gas6 effectively inhibit TLR-induced cytokine production in mouse dendritic cells and macrophages [5, 6, 12, 13] . For example, TAM activation by Gas6 inhibits production of inflammatory cytokines, such as TNF-, induced by TLR3, 4, and 9 [6] . Taken together with the recent findings regarding the role of innate immunity in intestinal tumorigenesis [2] [3] [4] , it 4 may be beneficial to investigate the potential involvement of TAM receptors and their ligands in intestinal tumor progression.
Among TAM receptors and two ligands, Axl and Gas6 have been particularly focused on in the field of tumor biology. Axl is associated with clinical outcome of leukemia, melanoma, and lung, prostate, ovarian, renal, thyroid, and gastric cancers [14] [15] [16] [17] [18] . Axl has transforming effects on human cancer cell lines [19, 20] . In contrast, although several reports have demonstrated the role of Gas6 in tumorigenesis by using cancer cell lines [15, 16, 21] , the in vivo role of Gas6 in mouse tumor development or human colorectal cancer progression remains to be elucidated.
In this study, we sought to investigate the role of Gas6 during tumorigenesis in in vivo intestines using Gas6 +/+ and Gas6 -/-mice.
Materials & Methods

Cell culture and reagents
Human colorectal cancer cell lines (SW480 and HT29) and a human macrophage cell line (THP-1) were obtained from the American Type Culture Collection (Manassas, VA, USA). Cell lines were cultured in RPMI-1640 (Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal calf serum (FCS). Recombinant human Gas6, a -glutamyl carboxylated active form, was purchased from R&D Systems (Minneapolis, MN, USA).
Cell proliferation assay
SW480 and HT29 cells were seeded at a density of 2.5  10 3 per well in 96-well tissue culture plates; after 24 hours, the medium was changed to FCS-free medium. After 24-hour incubation under the indicated conditions, cell proliferations were measured using the MTS assay (Cell Counting Kit 8; Dojindo, Kumamoto, Japan) according to the manufacturer's protocol.
Animal model of colitis and intestinal tumorigenesis
Generation of Gas6 knockout mouse with a C57/BL6 background was described previously [22] . Apc Min mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Animals were housed under specific pathogen-free conditions at the Animal Figure 1A) . To analyze the severity of colitis, mice were sacrificed after the administration of 2.5% DSS for 7 days (Supplementary Figure 1B) .
Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted using Trizol (Invitrogen were stained with anti-Gas6 antibody and to be 'low' when < 50% of the tumor cells were stained with anti-Gas6 antibody. The number of infiltrating CD45-positive leukocytes was counted in randomly selected 3 high power fields (× 400) in each specimen, and the mean number was determined.
Statistical analysis
Results are presented as the mean values ± standard deviations unless otherwise stated.
Difference between treatment, group, and strains were analyzed using the two-tailed Student's t test, chi-square test, Fisher's exact test, ANOVA, and Bonferroni's test.
Survival rates were estimated by the Kaplan-Meier method and compared using the Gehan-Breslow-Wilcoxon test.
Results
Gas6 enhanced the proliferation of colorectal cancer cells and suppressed the activation of macrophages in vitro
Previous reports using cancer cell lines have suggested that Gas6 contributes to tumor progression [15, 16, 21] . 
Gas6 deficiency enhanced mouse colitis-associated tumorigenesis
Next, we investigated whether Gas6 affects mouse colitis-associated tumorigenesis.
Under physiological conditions, the status of epithelial cells, stromal infiltration by inflammatory cells, and mRNA expression of TAM receptors were not altered in relation to the Gas6 gene dosage (data not shown). However, after azoxymethane/dextran sulfate sodium (AOM/DSS) treatment (Supplementary Figure   1A ), the number of polyps in the Gas6 -/-mouse colon was significantly greater than that in the Gas6 +/+ mouse colon ( Figure 2A and B). Consistent with this, mRNA expression of proliferation cell nuclear antigen (PCNA) in the colonic polyps of the Gas6 -/-mice was significantly higher than that in the polyps of the Gas6 +/+ mice ( Figure 2C ).
Infiltration of neutrophils and macrophages into colonic polyps of the Gas6 -/-mice was more prominent ( Figure 2D ). In addition, mRNA expression of inflammatory cytokines, such as TNF-, CXCL1, and CCL2 was significantly upregulated in the colonic polyps of the Gas6 -/-mice ( Figure 2E ). NFB was also significantly activated (phosphorylation of p65) in the colonic polyps of the Gas6 -/-mice ( Figure 2F ). The mRNA expression of representative tumor-promoting factors, such as c-Myc and Cox2 (Ptgs2), was significantly upregulated in the colonic polyps of the Gas6 -/-mice ( Figure 2G ). After AOM/DSS treatment, survival of the Gas6 -/-mice was significantly shorter than that of the Gas6 +/+ mice (P < 0.01; Figure 2H ). Thus, contrary to in vitro studies,
Gas6 played an inhibitory role in colitis-associated tumorigenesis in mice.
Gas6 was increased locally and appeared to suppress immune responses of infiltrating stromal cells in DSS-induced mouse colitis
Persistent colitis is a risk factor for the progression of colonic tumors [24, 25] . Figure 1B) .
After administration of 2.5 % DSS for 7 days, the Gas6 -/-mice exhibited more severe colitis than the Gas6 +/+ mice. In the Gas6 -/-mice, the colonic crypt architecture was almost completely obliterated, with massive stromal infiltration by inflammatory cells, whereas in the Gas6 +/+ mice the crypt architecture was relatively preserved ( Figure 3A ).
The histological damage score [26] and weight loss of the DSS-treated Gas6 -/-mice were significantly greater than those of the DSS-treated Gas6 +/+ mice ( Figure 3B ).
Stromal infiltration by neutrophils and macrophages was more prominent in the DSS-treated Gas6 -/-mice ( Figure 3C ). Similarly, mRNA expression of TNF- CXCL1, and CCL2 was significantly higher in the DSS-treated Gas6 -/-mice ( Figure 3D ). Thus, Gas6 had inhibitory activity in mouse colonic inflammation in the DSS-treated mice as well as in AOM/DSS-treated mice.
In the DSS-treated Gas6 +/+ mouse colon, Gas6 mRNA expression was significantly increased ( Figure 4A ), suggesting that locally produced Gas6 plays a role in DSS-induced colitis. Therefore, we sought to evaluate the in vivo activation of targets of Gas6/TAM. The mRNA expression of Socs1/3, which are key mediators of Gas6/TAM signaling in the downregulation of TLR-mediated immune responses of macrophages [6] , was significantly lower in the DSS-treated Gas6 -/-mouse colon than in the DSS-treated Gas6 +/+ mouse colon ( Figure 4A ). ELISA showed that the phosphorylation level of nuclear p65, which is the downstream of TLRs and can be downregulated by Gas6/TAM signaling in macrophages [6] , increased significantly in the DSS-treated
Gas6
-/-mice ( Figure 4B ). Thus, we confirmed that the activation of TLR/Gas6/TAM signaling in DSS-induced colitis was altered according to the Gas6 genotype.
We next performed immunostainings to determine the cell types in which these downstream molecules of Gas6/TAM signaling were activated. Stainings for Socs3 and phosphorylated-p65 were only partially observed in the non-inflamed Gas6 +/+ and
-/-mouse colons ( Figure 4C , ascending, arrowheads). In contrast, Socs3 and phosphorylated-p65 were vigorously observed in mononuclear cells infiltrating the stroma especially in the inflamed part of the Gas6 -/-mouse colon ( Figure 4C , rectum).
Because mRNA expression of TAM receptors in stromal monocytes were slightly higher than those in epithelial cells (data not shown), these results suggest that locally increased levels of Gas6 suppresses innate immune responses in DSS-induced colitis by upregulation of Socs1/3 and downregulation of NFB in infiltrating stromal cells.
Gas6 from both epithelial cells and bone marrow (BM)-derived cells contributed to suppression of DSS-induced mouse colitis
Previous Figure 3D) . Thus, Gas6 from both epithelial cells and BM-derived cells may contribute to suppression of DSS-induced mouse colitis. Table 3 ). These results suggest that Gas6 plays an inhibitory role in human colorectal cancer progression and suppression of local inflammatory responses.
Gas6 deficiency enhanced intestinal tumorigenesis in the Apc
Discussion
Previous studies have suggested that Gas6 promotes cancer cell progression in vitro [15, 16] . A previous study demonstrated that Gas6 produced from BM-derived cells enhances proliferation of subcutaneously transplanted murine colon cancer cells lacking Gas6 [21] . In this study, we also observed that Gas6 weakly, but significantly, enhances proliferation of human cancer cell lines. Importantly, these effects of Gas6 are exerted at cellular levels. The role of Gas6 should be complicated during in vivo intestinal tumorigenesis, because the intestines are inhabited by a vast population of microbes that play important roles in intestinal tumorigenesis [1] [2] [3] [4] . In line with previous studies [5, 6, 12, 13] , we also showed that Gas6 suppressed innate immune responses of a human monocyte cell line.
We analyzed AOM/DSS intestinal tumor formation model, and revealed that the number of polyps in the Gas6 -/-mice was greater than that in the Gas6 +/+ mice.
Persistent colitis is a well-known risk factor for the progression of colonic tumors both in humans and mice [24, 25] . In our study, because the DSS-treated Gas6 -/-mice exhibited more severe colitis than the DSS-treated Gas6 +/+ mice, it can be reasoned that the absence of Gas6 and its anti-inflammatory activity was responsible for the increased number of polyps in the AOM/DSS-treated Gas6 -/-mice. Thus, in contrast to its in vitro behavior, the property of Gas6 to inhibit inflammatory cytokine production [5, 6, 12, 13], appears to exert an important negative effect on mouse intestinal tumorigenesis.
In monocyte lineages, Gas6/TAM signaling suppresses NFB activation and inflammation through the induction of Socs1/3 [5, 6] . It should be noted that similar to the AOM/DSS colitis mice, in the Apc Min mouse model in our study, the number of polyps in the Gas6 -/-mice was greater than that in the Gas6 +/+ mice, thereby resulting in significantly severe anemia and shorter survival. In contrast to the AOM/DSS colitis mouse, the Apc Min mouse is not characterized by the presence of obvious intestinal inflammation. However, polyps from both AOM/DSS and Apc Min mice are exposed to LPS-producing luminal bacteria. Lack of TLR signaling or microbes suppresses Apc Min mouse intestinal tumorigenesis [3, 4] . Furthermore, lack of TNF-, a key inflammatory cytokine that induces NFB activation, significantly reduces intestinal polyp formation in Apc Min mice [25] . In our study, the activity of NFB, a downstream target of TLR signaling, and TNF- mRNA levels were significantly higher in the Gas6 -/-mice than in the Gas6 +/+ mice with either AOM/DSS treatment or Apc Min genotype. Consistent with these data, Cox2 (Ptgs2), a key tumor-promoting factor regulated by NFB, was also significantly elevated in the
Gas6
-/-mice. Therefore, activation of the TLR/TNF--NFB-Cox2 pathways appears to be one of the important events that promote intestinal tumorigenesis in the absence of Gas6 in both AOM/DSS-treated and Apc Min mouse models.
In humans, we found that higher expression of Gas6 in the cancer tissues was associated with longer survival and a milder local inflammatory responses in colorectal cancer patients. These data are consistent with our murine models and with a previous study showing that high Gas6 expression was associated with better prognosis of renal cancer patients [18] . However, a recent report showed that the activation of AXL is associated with the resistance to EGFR-targeted therapy in lung cancer [16] . In addition,
it is important to note that warfarin, which has an inhibitory effect on Gas6 activity by blocking vitamin K-dependent -glutamyl carboxylation, is widely used as an anticoagulant. As for the association between warfarin use and the prognosis of cancer patients, a recent large cohort study showed that the effect of warfarin on patient survival was identical to that of placebo in gastrointestinal cancers [28] . Thus, the role of Gas6 and related factors appears complex, and further studies are required to determine the comprehensive role of Gas6 and TAM receptors in colorectal cancer patients.
In conclusion, we demonstrated that Gas6 has an inhibitory effect on intestinal 
